Organon Q3 revenue $1.52B, adj. EPS $0.87; narrows & lowers FY2023 guidance

Organon & Co.

2023-Q3 EPS reported $1.86 revenue$4,665,000,000

Revenue $1,519M (-1% YoY); diluted EPS $0.23; non-GAAP adj. diluted EPS $0.87.
Women's Health -7% ex-FX; Biosimilars +10% ex-FX; Established Brands +3% ex-FX.
Board declares quarterly dividend $0.28 per share, unchanged.
FY2023 revenue guidance narrowed to $6.15-6.25B (prev. $6.15-6.35B); adj. EBITDA margin 30.5-31.5% (prev. 31-33%).
Adjusted EBITDA $447M, margin 29.4% vs 35.5% a year ago.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Organon & Co. reported third quarter ended September 30, 2023 results: revenue $1,519 million, net income $58 million, EPS $0.23. Guidance lowered.

Period: third quarter ended September 30, 2023
Revenue: $1,519 million
Net income: $58 million
EPS: $0.23
Guidance: lowered
Result: reported results

Exact text from the filing

Organon Reports Results for the Third Quarter Ended September 30, 2023 • Third quarter 2023 revenue of $1,519 million • Third quarter 2023 diluted earnings per share of $0.23

View on SEC.gov

Browse all earnings releases →

Organon & Co. filing history →

Source: SEC EDGAR

accession 0001104659-23-113589

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.